Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...
Repatha is now available for a monthly cash price of $239, through AmgenNow and GoodRx. Repatha (evolucumab) is now avaliable ...
THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
The FDA has expanded approval of Amgen’s PCSK9 inhibitor Repatha (evolocumab), permitting use in adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL cholesterol, ...
Repatha will be available through AmgenNow for $239 per month, which is nearly 60% less than its current list price in the U.S. The company said that the new price for Repatha is the lowest among the ...
Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol-lowering medication Repatha at a discounted cash ...
Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction ...
* Top-line results from approximately 27,500-patient event-driven fourier study are anticipated in q1 of 2017 Sign up here. * Amgen Inc - "effect of repatha on cardiovascular morbidity and mortality ...
TipRanks on MSN
Amgen Stock (AMGN) Falls as It Cuts 60% Off Cholesterol Drug Price, Heeding Trump’s Clamor
Top American pharmaceutical firm Amgen ($AMGN) on Monday unwrapped AmgenNow, its new direct-to-consumer platform. It kicked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback